Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia?-Reference-Cited by-同舟云学术

Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia?

Published:2019-09-13 Issue:11 Volume:19 Page:7573-7587
ISSN:1530-6984
Container-title:Nano Letters
language:en
Short-container-title:Nano Lett.

Author:

Obaid Girgis¹^ORCID,Bano Shazia¹,Mallidi Srivalleesha¹,Broekgaarden Mans¹,Kuriakose Jerrin¹,Silber Zachary¹,Bulin Anne-Laure¹,Wang Yucheng¹,Mai Zhiming¹,Jin Wendong¹,Simeone Diane²,Hasan Tayyaba¹³

Affiliation:

1. Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States

2. Department of Surgery and Department of Pathology, Perlmutter Cancer Center, New York University Langone Health, New York, New York 10016, United States

3. Division of Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

Funder

National Institutes of Health

Higher Education Commission, Pakistan

Bullock-Wellman Fellowship

Publisher

American Chemical Society (ACS)

Subject

Mechanical Engineering,Condensed Matter Physics,General Materials Science,General Chemistry,Bioengineering

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.nanolett.9b00859

Reference104 articles.

1. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer